COSCIENS Biopharma Inc T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc > Now optimized to bring transformational products to market

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Jun 24, 2024 8:10am

110 Views

Post# 36102882

Now optimized to bring transformational products to market

Ronald W. Miller, Chair of the Company: “With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”

Does AEZS now have critical mass to support a Canadian sales team for the Canadian market and some border states?

PGX-YBG immune booster
PGX-YBG/CoQ10
Oat beta glucan chewy
Juvente
Growth hormone deficiency diagnostic

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide